Archives
-
Batimastat (BB-94) Workflows for MMP Research
2026-08-24
Batimastat (BB-94) combines broad-spectrum MMP inhibition with a practical workflow for separating proteolysis, extracellular-matrix remodeling, and cell-intrinsic effects. This guide connects biochemical assays with localized BDNF-processing studies, neuromuscular-junction models, and preclinical tumor research while emphasizing controls and troubleshooting.
-
Vasopressin Analogues: Mechanisms and Translation
2026-08-24
The reference review explains how structural changes to vasopressin reshape receptor selectivity, metabolic stability, duration of action, and therapeutic potential. Its comparison of lypressin, desmopressin, terlipressin, ornipressin, and non-peptide ligands provides a framework for designing receptor, endocrine, vascular, and exploratory antiviral studies.
-
Obeticholic Acid for FXR Liver Research
2026-08-23
Obeticholic Acid provides a mechanism-focused way to activate FXR, quantify bile acid homeostasis, and connect hepatocyte transcriptional responses with liver fibrosis and inflammation endpoints. This practical workflow shows how to use it alongside the Notch–NK findings from a recent fibrosis study without overinterpreting cross-pathway evidence.
-
PTPN2 Targets the STING–STAT3 Axis in Psoriasis
2026-08-22
A 2026 Immunobiology study identifies PTPN2 as a negative regulator of the STING–STAT3 pathway in psoriasis-like inflammation. Using keratinocyte and imiquimod-induced mouse models, the authors show that PTPN2 suppresses inflammatory signaling while promoting autophagy and apoptosis, with additional benefit from rapamycin.
-
Rotigotine hydrochloride for PD Research
2026-08-22
Build route-aware Parkinson’s disease and neuroprotection workflows with Rotigotine hydrochloride, from SH-SY5Y screening to 6-OHDA cystometry. The reference study shows why intravenous and subcutaneous exposure should not be treated as interchangeable when studying motor or lower-urinary-tract phenotypes.
-
Zoledronic Acid: Cancer and Bone Workflows
2026-08-21
Build more reproducible Zoledronic Acid experiments by connecting dose–time apoptosis profiling with bone-disease endpoints and formulation controls. This practical guide distinguishes nominal exposure from delivered exposure across breast cancer, myeloma, and osteolytic disease models.
-
Bufalin-CRISPR Nanomedicine Reprograms CRC Immunity
2026-08-20
Liu et al. describe a calcium lactate nanoparticle that co-delivers bufalin and a CD47-targeting CRISPR/Cas9 ribonucleoprotein for colorectal cancer. The platform combines tumor-cell pyroptosis and apoptosis with macrophage M1 reprogramming and enhanced phagocytosis, providing a mechanistic framework for local and systemic antitumor immunity.
-
LGK-974: From Wnt Blockade to Phenotype
2026-08-20
LGK-974 is a selective PORCN inhibitor that connects Wnt pathway target engagement with measurable tissue and tumor phenotypes. This article uses recent sclerosteosis research to develop a cross-domain framework for interpreting LGK-974 assays in cancer and bone biology.
-
Stattic: A Practical STAT3 Inhibitor Guide
2026-08-19
Stattic is a small-molecule STAT3 inhibitor used to examine STAT3-dependent transcription, proliferation, apoptosis induction in cancer cells, and radiosensitization. Product data report micromolar activity in several HNSCC cell lines, while peer-reviewed lymphatic-endothelial research shows that pharmacologic STAT3 inhibition can block cadmium-induced cellular responses.
-
2-NBDG: Turning Glucose Uptake Into Mechanistic Insight
2026-08-19
A translational framework for using 2-NBDG to connect transporter activity, intracellular glucose handling, and pathway biology in gestational diabetes and broader metabolic research.
-
KPT330 and Precision CRISPR-Cas9 Editing
2026-08-18
The reference study identifies selective inhibitors of nuclear export, including KPT330, as indirect modulators of Cas9 activity. By altering Cas9 mRNA export rather than directly blocking the nuclease, these compounds improved the precision of genome and base editing in human cells and broadened the options for temporal control of CRISPR systems.
-
Low-Molecular-Weight Inhibitors of Complement
2026-08-18
This 2023 invited review explains how drug discovery has translated alternative complement pathway biology into potent, selective, orally available low-molecular-weight inhibitors of factor B and factor D. Its main practical contribution is a framework linking convertase pharmacology with pathway-selective serum assays, disease models, and clinical development across complement-mediated disorders.
-
L-Threonine Workflows for Metabolic Profiling
2026-08-17
Use L-Threonine to build controlled nutrient-perturbation experiments for cell culture optimization, metabolic profiling, and nutritional intervention studies. Pairing these workflows with a metal-free alkaline phosphatase assay adds an orthogonal phenotype readout without incorrectly treating L-Threonine as a direct ALP inhibitor or ligand.
-
Podophyllotoxin Derivative 5p and Drug Resistance
2026-08-17
The reference study shows that podophyllotoxin derivative 5p simultaneously inhibits topoisomerase IIα catalytic activity and microtubule polymerization. This dual mechanism was associated with activity against drug-resistant breast and oral cancer models, altered efflux-transporter expression, mitotic arrest, apoptosis, pyroptosis-related signals, and suppression of resistant tumor growth in mice.
-
Apicidin Disrupts Oocyte Maturation and Histone Acetylation
2026-08-16
The reference study identifies a reproductive-toxicity mechanism for Apicidin, showing that exposure impairs oocyte meiotic maturation through spindle, chromosome, actin, and histone-acetylation abnormalities. Its integrated cellular and epigenetic design provides a useful framework for evaluating how an established histone deacetylase inhibitor and emerging mycotoxin may compromise oocyte quality.